



OPEN ACCESS

EDITED AND REVIEWED BY
Kristin Higgins,
Winship Cancer Institute, Emory
University, United States

*CORRESPONDENCE

Nan Bi
binan_email@163.com

[†]These authors have contributed
equally to this work.

SPECIALTY SECTION

This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 31 July 2022

ACCEPTED 01 August 2022

PUBLISHED 24 August 2022

CITATION

Yang Y, Wang J, Wang W, Zhang T,
Zhao J, Wang Y, Li Y, Wang L and
Bi N (2022) Corrigendum:
progression-free survival and time to
progression as potential surrogate
endpoints for overall survival in
chemoradiotherapy trials in limited-
stage small-cell lung cancer: A
systematic review and meta-analysis.
Front. Oncol. 12:1007862.
doi: 10.3389/fonc.2022.1007862

COPYRIGHT

© 2022 Yang, Wang, Wang, Zhang,
Zhao, Wang, Li, Wang and Bi. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Yin Yang^{1†}, Jianyang Wang^{1†}, Wenqing Wang¹, Tao Zhang¹,
Jingjing Zhao¹, Yu Wang¹, Yexiong Li¹, Luhua Wang²
and Nan Bi^{1*}

¹Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

KEYWORDS

Limited-stage small-cell lung cancer, surrogate endpoint, overall survival, progression-free survival, time to progression, chemoradiotherapy

A Corrigendum on

[Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis](#)

by Yang Y, Wang J, Wang W, Zhang T, Zhao J, Wang Y, Li Y, Wang L and Bi N (2022) *Front. Oncol.* 12:810580. doi: 10.3389/fonc.2022.810580

In the published article, there was an error in the legend for [Figure 1](#) and [Figure 3](#) as published, regarding the light green zone for 95% prediction intervals. The corrected legends appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1

Trial-level correlation between hazard ratios for OS and PFS/TTP in phase III RCTs. Green circles represent trials with a size proportional to the number of patients, blue line for the estimated regression line and the light green zone for 95% confidence intervals. OS, overall survival; PFS/TTP, progression free survival/time to progression; RCTs, randomized controlled trials.




FIGURE 3
 Treatment arm-level correlation between 5-year OS and 1-year PFS/TTP (A), 2-year PFS/TTP (B), 3-year PFS/TTP (C), 4-year PFS/TTP (D), 5-year PFS/TTP (E) in phase III RCTs. Green circles represent treatment arms with a size proportional to the number of patients, blue lines for the estimated regression lines and the light green zones for 95% confidence intervals. OS, overall survival; PFS/TTP, progression free survival/time to progression; RCTs, randomized controlled trials.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.